ClinicalTrials.gg
RecruitingNCT07625358PACUpdated Nov 16, 2026

Investigating the Effect of Caffeine and Alcohol on Pupil Dynamics

An interventional study of Placebo Comparator: Placebo and Caffeine administration in Caffeine, Alcohol and Pupillary Response, sponsored by National University of Singapore. Recruiting at 1 site in Singapore. Open to participants aged 30 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by National University of Singapore · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 16, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
30 Years to 50 Years
Sex
All
01

Study summary

The goal of this study is to understand how caffeine and alcohol affect the ocular and physiological systems, especially how the pupil (the aperture in the colored part of the eye) responds to light. It will also test whether these changes can be used to detect recent caffeine or alcohol intake using a portable eye device.

The main questions it aims to answer are:

  1. How does caffeine change pupil responses, eye movements, and other ocular and physiological measurements?
  2. How does alcohol change these same ocular and physiological responses?
  3. Are the effects of caffeine and alcohol different from each other?
  4. Can these changes be used to accurately identify whether someone has consumed caffeine or alcohol?

Researchers will compare caffeine, alcohol, and a placebo (a look-alike drink with no active substance) to see how each affects the ocular and physiological outcomes.

Participants will:

  1. Attend three separate sessions where they will consume caffeine, alcohol, or a placebo (in random order)
  2. Undergo pupillary response evaluation using a handheld device that measures responses to different colored light stimuli
  3. Have their eye movements analyzed
  4. Have retinal and choroidal thickness, blood perfusion, and ocular oxygen levels measured
  5. Have basic body measurements recorded (such as pulse rate and blood pressure)
  6. Complete tests at multiple time points over 2 hours after consumption

The results of this study may help develop a quick and non-invasive way to detect recent caffeine or alcohol use for clinical and safety purposes.

Read the detailed description

Caffeine and alcohol are widely consumed psychoactive substances that affect the central and autonomic nervous systems. These effects can influence ocular function, including pupil responses to light, eye movements, and retinal physiology. However, objective and non-invasive methods to detect and differentiate these effects remain limited.

The pupillary light reflex is a sensitive indicator of autonomic nervous system activity. Chromatic pupillometry, which uses different colored light stimuli, allows assessment of specific retinal pathways and provides detailed information about pupil function. This study aims to determine whether changes in pupillary responses and other ocular measurements can be used to detect recent caffeine or alcohol consumption.

Study Design and Procedures A total of 100 healthy adults aged 30-50 years will participate in this study.

Each participant will attend three study visits, corresponding to the following conditions:

  1. Caffeine condition (\~3 mg/kg)
  2. Alcohol condition (target blood alcohol concentration \~0.05%)
  3. Placebo condition The order of conditions will be randomized. This is a double-masked, within-subject crossover study, where each participant undergoes all three conditions.

Study Visit Procedures

At each visit, participants will receive one tablet and one beverage according to the assigned condition:

  1. Placebo condition: placebo tablet with a non-alcoholic beverage
  2. Alcohol condition: placebo tablet with an alcohol-containing beverage
  3. Caffeine condition: caffeine tablet with a non-alcoholic beverage Procedures will be standardized to maintain masking, and study personnel performing assessments will remain unaware of the assigned condition.

Assessments All measurements will be performed at baseline (before consumption) and at 30, 60, 90, and 120 minutes after consumption, unless otherwise specified.

  1. Pupillary Assessment: Pupillary responses will be measured using a handheld chromatic pupillometry device in a controlled dark environment. Different colored light stimuli will be used to assess pupil function.
  2. Eye Movement Analysis: Eye movements will be recorded to evaluate oculomotor function, including tracking, fixation, and gaze behavior at baseline, 60 minutes, and 120 minutes.
  3. Retinal and Choroidal Imaging: Retinal and choroidal thickness and blood perfusion will be measured using optical coherence tomography (OCT) and OCT angiography at baseline, 60 minutes, and 120 minutes.
  4. Breath Alcohol Measurement: Breath alcohol concentration will be measured using a breathalyzer at all time points to monitor alcohol levels.
  5. Physiological Measurements: Basic physiological parameters will be recorded, including: Pulse rate, Blood pressure, Blood Oxygen saturation

Data Analysis Data from pupillary responses, eye movements, retinal imaging, and physiological measurements will be combined to identify patterns associated with caffeine and alcohol intake.

Expected Outcomes This study aims to identify measurable changes in pupil responses and other ocular parameters following caffeine and alcohol consumption. It will also evaluate whether a portable, non-invasive system can be used to detect alcohol and caffeine consumption.

The findings may support the development of rapid and objective screening tools for clinical, occupational, and public safety applications.

02

Conditions studied

  • Caffeine
  • Alcohol
  • Pupillary Response
  • Eye Movements
  • Optical Coherence Tomography
  • Optical Coherence Tomography Angiography
  • Physiological Responses

Keywords

  • Caffeine
  • Alcohol
  • Pupillary light reflex
  • Pupillometry
  • Chromatic pupillometry
  • Eye movements
  • Oculomotor function
  • Optical coherence tomography
  • Optical coherence tomography angiography
  • Physiological responses
  • Machine learning
  • Non-invasive monitoring
03

In context

Lead sponsor

National University of Singapore is the lead sponsor of 212 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Participants must meet the inclusion criteria, as shown below, to participate in this study

Inclusion criteria

Inclusion Criteria

  1. Age: 30 to 50 years of age
  2. Visual Acuity: Best Corrected Visual Acuity (BCVA) of 0.20 LogMAR or better in both eyes
  3. Ability to provide : Participants must be able to understand and sign the informed consent form
  4. Ability to consume both caffeine and alcohol: Participants must be willing and able to consume caffeine and alcohol as part of the study

Participants meeting any of the exclusion criteria, as shown in the table below, will be excluded from participation.

Exclusion criteria

Exclusion Criteria

  1. Diagnosed ocular conditions: Participants with ocular or ocular movement diseases such as glaucoma, age-related macular degeneration, diabetic retinopathy, amblyopia, severe ptosis, or conditions relating to pupils: anisocoria, irregular pupil, Adie tonic, Horner's syndrome, Argyll Robertson pupil, etc. These exclude cataracts, refractive errors, and any ocular condition not affecting vision or ocular movement or obstructing the pupil.
  2. Diagnosed and unresolved neurological conditions:Stroke, unresolved traumatic brain injury, space-occupying lesions in the brain, neuropathies, demyelinating conditions, nerve palsies, etc.
  3. Diagnosed systemic conditions that may restrict the participant from drinking caffeine or alcohol: Hypertension, cardiovascular disease, liver disease, kidney disease, etc.
  4. Medications: Participants taking any medications that may interact with caffeine or alcohol, affect alertness, or cause drowsiness
  5. Previous complex intraocular eye surgery: Participants who have undergone any eye surgery other than uncomplicated refractive surgery.
  6. Pregnancy or breastfeeding: Pregnant or breastfeeding women will be excluded from the study, as caffeine and alcohol can affect the fetus or baby
  7. History of substance abuse: Participants with a history of substance abuse
  8. Allergies or sensitivities: Participants with allergies or sensitivities to caffeine or alcohol
  9. Shift work or having travelled across 2 time zones over the past 2 weeks: This is essential to avoid any impact of sleep deprivation on our outcome measures
  10. Non-consumers or light-consumers of caffeine and alcohol Participants who are light consumers of caffeine or alcohol will be excluded due to higher sensitivity to side effects.

Caffeine: If less than 100 mg of caffeine per week from all sources (including coffee, soft drinks, energy drinks, chocolate, and medications) based on the CCQ* Alcohol: If AUDIT-C** score less than 1

11- Extremely frequent consumers Participants who are extremely frequent consumers of caffeine or alcohol will be excluded due to potential withdrawal symptoms during the required 18-hour abstinence and possible reduced sensitivity to administered doses.

Caffeine: If more than 400mg of caffeine (e.g., 5 espressos) per day from all sources (including coffee, soft drinks, energy drinks, chocolate, and medications) based on the CCQ* Alcohol: If AUDIT-C** scores more than 4 for men and more than 3 for women

Note: Participants will complete a history update questionnaire at each laboratory visit to report any changes relevant to the exclusion criteria. If a participant no longer meets the eligibility criteria at any visit after the baseline assessment, the visit will either be rescheduled, if appropriate, or the participant will be withdrawn from the study. Reimbursement will be provided on a prorated basis.

*CCQ: Caffeine Consumption Questionnaire

**AUDIT-C: Alcohol Use Disorders Identification Test-C

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants receive placebo tablets and non-active beverage under double-masked crossover conditions.

    Other: Placebo Comparator: Placebo

  • Experimental
    Caffeine

    Participants receive caffeine administration under double-masked crossover conditions.

    Other: Caffeine administration

  • Experimental
    Alcohol

    Participants receive alcohol administration under double-masked crossover conditions.

    Other: Alcohol (Ethanol)

Interventions

  • OtherPlacebo Comparator: Placebo

    Participants receive a matched placebo tablet together with a non-alcoholic beverage identical in appearance and volume to the active conditions. A cornstarch-based formulation may be used for the placebo tablet. Beverage presentation is standardized to maintain blinding across study conditions. No active caffeine or alcohol is administered.

  • OtherCaffeine administration

    Participants receive a single oral dose of caffeine (\~3 mg/kg body weight) administered in tablet form. The caffeine is given with a non-alcoholic beverage matched to study conditions. All procedures are performed under randomized, double-masked crossover design conditions.

  • OtherAlcohol (Ethanol)

    Participants consume a standardized alcoholic beverage designed to achieve a target blood alcohol concentration of approximately 0.05%. A placebo tablet is administered alongside the beverage to maintain masking. All procedures are performed under randomized, double-masked crossover design conditions.

06

What researchers measure

Primary outcomes

  1. Baseline Pupil Size

    Baseline pupil size will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Baseline pupil size refers to the resting pupil diameter measured prior to light stimulation. It is measured in pixels.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  2. Phasic Pupil Constriction to Blue Light

    Phasic pupil constriction to blue light will be quantified using handheld chromatic pupillometry. Phasic pupil constriction to blue light refers to the rapid, transient decrease in pupil diameter that occurs immediately after the onset of a blue light stimulus. It is calculated as a percentage change from baseline.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  3. Maximum Pupil Constriction to Blue Light

    Maximum pupil constriction to blue light will be quantified using handheld chromatic pupillometry. Maximum pupil constriction to blue light refers to the greatest reduction in pupil diameter observed following the onset of a blue light stimulus. It is calculated as a percentage change from baseline.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  4. Pupil Constriction Latency to Blue Light

    Pupil constriction latency to blue light will be quantified using handheld chromatic pupillometry. Constriction latency is defined as the time from blue light onset to the first detectable decrease in pupil diameter relative to baseline. It is measured in seconds or milliseconds.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  5. Phasic Pupil Constriction to Red Light

    Phasic pupil constriction to red light will be quantified using handheld chromatic pupillometry. Phasic pupil constriction to red light refers to the rapid, transient decrease in pupil diameter that occurs immediately after the onset of a red light stimulus. It is calculated as a percentage change from baseline.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  6. Maximum Pupil Constriction to Red Light

    Maximum pupil constriction to red light will be quantified using handheld chromatic pupillometry. Maximum pupil constriction to red light refers to the greatest reduction in pupil diameter observed following the onset of a red light stimulus. It is calculated as a percentage change from baseline.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  7. Pupil Constriction Latency to Red Light

    Pupil constriction latency to red light will be quantified using handheld chromatic pupillometry. Constriction latency is defined as the time from red light onset to the first detectable decrease in pupil diameter relative to baseline. It is measured in seconds or milliseconds.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  8. Phasic Pupil Constriction to Continuous White Light

    Phasic pupil constriction to continuous white light will be quantified using handheld chromatic pupillometry. Phasic pupil constriction to white light refers to the rapid, transient decrease in pupil diameter that occurs immediately after the onset of a white light stimulus. It is calculated as a percentage change from baseline.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  9. Maximum Pupil Constriction to Continuous White Light

    Maximum pupil constriction to continuous white light will be quantified using handheld chromatic pupillometry. Maximum pupil constriction to white light refers to the greatest reduction in pupil diameter observed following the onset of a white light stimulus. It is calculated as a percentage change from baseline.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  10. Pupil Constriction Latency to Continuous White Light

    Pupil constriction latency to continuous white light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Constriction latency is defined as the time from white light onset to the first detectable decrease in pupil diameter relative to baseline. It is measured in seconds.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  11. Maximum Pupil Constriction to White Light Flash

    Maximum pupil constriction to white light flash will be quantified using using handheld chromatic pupillometry. Maximum pupil constriction to white light refers to the greatest reduction in pupil diameter observed following the onset of a white light stimulus. It is calculated as a percentage change from baseline.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  12. Post-Stimulus Pupil Recovery Slope to Blue Light

    Post-stimulus pupil recovery slope to blue light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Post-stimulus pupil recovery slope refers to the rate of pupil re-dilation following the offset of a blue light stimulus. It is calculated as percentage change per second.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  13. Pupil Slope to Blue Light 1.7s before Blue Light Offset

    Pupil slope to blue light 1.7s before blue light offset will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Pupil slope to blue light within the last 1.7s refers to the rate of pupil re-dilation just before the offset of a blue light stimulus. It is calculated as percentage change per second.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  14. Pupil Slope to Blue Light 1.7s after Blue Light Offset

    Pupil slope to blue light in the 1.7s after blue light offset will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Pupil slope to blue light in the 1.7s after blue light offset refers to the rate of pupil re-dilation just after the offset of a blue light stimulus. It is calculated as percentage change per second.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  15. Post-Stimulus Pupil Recovery Slope to Red Light

    Post-stimulus pupil recovery slope to red light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Post-stimulus pupil recovery slope refers to the rate of pupil re-dilation following the offset of a red light stimulus. It is calculated as percentage change per second.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  16. Post-Stimulus Pupil Recovery Slope to White Light Flash

    Post-stimulus pupil recovery slope to white light flash will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Post-stimulus pupil recovery slope refers to the rate of pupil re-dilation following the offset of a white light stimulus. It is calculated as percentage change per second.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  17. Post-Stimulus Pupil Recovery Slope to Continuous White Light

    Post-stimulus pupil recovery slope to continuous white light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. Post-stimulus pupil recovery slope refers to the rate of pupil re-dilation following the offset of a white light stimulus. It is calculated as percentage change per second.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  18. PIPR at 6 s - Blue Light

    Post-illumination pupillary responses (PIPR) to blue light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR at 6 s is measured as pupil size at 6 seconds after blue light offset. It is calculated as a percentage of baseline pupil size.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  19. PIPR at 12 s - Blue Light

    Post-illumination pupillary responses (PIPR) to blue light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR at 12 s is measured as pupil size at 12 seconds after blue light offset. It is calculated as a percentage of baseline pupil size.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  20. PIPR Area Under the Curve (0-12 s) - Blue Light

    Post-illumination pupillary responses (PIPR) to blue light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR area under the curve (AUC) from 0 to 12 seconds captures the total magnitude and duration of the sustained post-illumination response. It is calculated as the integrated area in %.s.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  21. PIPR at 6 s - Red Light

    Post-illumination pupillary responses (PIPR) to red light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR at 6 s is measured as pupil size at 6 seconds after red light offset. It is calculated as a percentage of baseline pupil size.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  22. PIPR Area Under the Curve - Red Light

    Post-illumination pupillary responses (PIPR) to red light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR area under the curve (AUC) from 0 to end of recording captures the total magnitude and duration of the sustained post-illumination response. It is calculated as the integrated area in %.s.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  23. PIPR at 6 s - Flash White Light

    Post-illumination pupillary responses (PIPR) to white light flash will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR at 6 s is measured as pupil size at 6 seconds after white light offset. It is calculated as a percentage of baseline pupil size.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  24. PIPR at 6 s - Continuous White Light

    Post-illumination pupillary responses (PIPR) to continuous white light will be quantified using chromatic pupillometry with a handheld chromatic pupillometer. PIPR refers to the sustained pupil constriction that persists after the termination of a light stimulus. PIPR at 6 s is measured as pupil size at 6 seconds after white light offset. It is calculated as a percentage of baseline pupil size.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

Secondary outcomes

  1. Retinal Thickness

    Retinal thickness will be assessed using Triton swept-source optical coherence tomography (SS-OCT). Retinal thickness is defined as the axial distance between the internal limiting membrane and the retinal pigment epithelium, measured in micrometres (µm), and is automatically quantified across the nine ETDRS subfields of the 12 × 9 mm macular volume scan.

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  2. Choroidal Thickness

    Choroidal thickness will be assessed using swept-source optical coherence tomography (SS-OCT). Choroidal thickness is defined as the perpendicular distance between the outer boundary of Bruch's membrane and the chorioscleral interface, measured in micrometres (µm), and is automatically segmented across the nine ETDRS subfields.

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  3. Superficial Capillary Plexus Vessel Density

    Vessel density of the superficial capillary plexus (SCP) will be assessed using optical coherence tomography angiography (OCTA). Using the 6 × 6 mm macular OCTA scan, the SCP is automatically segmented by the built-in IMAGEnet software. Vessel density is defined as the proportion of the measurement area occupied by detected blood flow signals, reported as a percentage (%) across the whole image and individual ETDRS subfields.

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  4. Deep Capillary Plexus Vessel Density

    Vessel density of the deep capillary plexus (DCP) will be assessed using optical coherence tomography angiography (OCTA). Using the 6 × 6 mm macular OCTA scan, the DCP is automatically segmented by the built-in IMAGEnet software. Vessel density is defined as the proportion of the measurement area occupied by detected blood flow signals, reported as a percentage (%) across the whole image and individual ETDRS subfields.

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  5. Choriocapillaris Vessel Density

    Choriocapillaris vessel density will be assessed using optical coherence tomography angiography (OCTA). Using the 6 × 6 mm macular OCTA scan, the choriocapillaris slab is automatically segmented from 0 to 10.4 µm below the outer boundary of Bruch's membrane. Vessel density is defined as the proportion of the measurement area exhibiting detectable flow signal relative to the total sampled area, reported as a percentage (%).

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  6. Foveal Avascular Zone Area

    Foveal avascular zone (FAZ) area will be assessed using optical coherence tomography angiography (OCTA). Using the 6 × 6 mm macular OCTA scan, the FAZ is automatically delineated at the level of the superficial capillary plexus by the built-in IMAGEnet software. FAZ area is defined as the area of the capillary-free region centred on the fovea, measured in square millimetres (mm²).

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  7. Choroidal Vascularity Index

    The choroidal vascularity index (CVI) will be derived from the subfoveal horizontal B-scan of the 12 × 9 mm SS-OCT macular scan. The segmented choroidal region, bounded by Bruch's membrane and the chorioscleral interface, is binarised into luminal (vascular) and stromal areas. CVI is calculated as the ratio of luminal choroidal area to total choroidal area, expressed as a percentage (%).

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  8. Prosaccade Latency

    Prosaccade latency will be assessed using eye tracking. Prosaccade latency refers to the time interval between the onset of a visual target and the initiation of the corresponding prosaccade eye movement. It is measured in milliseconds (ms).

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  9. Prosaccade Peak Velocity

    Prosaccade peak velocity will be assessed using eye tracking. Prosaccade peak velocity refers to the maximum angular velocity achieved during a prosaccade movement. It is measured in degrees per second (°/s).

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  10. Prosaccade Amplitude

    Prosaccade amplitude will be assessed using eye tracking. Prosaccade amplitude refers to the total angular displacement of the eye during a prosaccade movement. It is measured in degrees (°).

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  11. Smooth Pursuit Gain

    Smooth pursuit gain will be assessed using eye tracking. Smooth pursuit gain refers to the ratio of eye velocity to target velocity during smooth pursuit tracking, where a value of 1.0 indicates perfect tracking. It is expressed as a unitless ratio.

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  12. Catch-Up Saccade Frequency During Smooth Pursuit

    Catch-up saccade frequency will be assessed using eye tracking. Catch-up saccade frequency refers to the number of corrective saccades per second that occur during smooth pursuit tracking, reflecting the degree of pursuit impairment. It is measured as events per second (events/s).

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  13. Smooth Pursuit Tracking Accuracy

    Smooth pursuit tracking accuracy will be assessed using eye tracking. Smooth pursuit tracking accuracy refers to the proportion of time the eye position is within an acceptable error window of the pursuit target trajectory. It is calculated as a percentage (%).

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  14. Micro-Saccade Rate During Fixation

    Micro-saccade rate will be assessed using eye tracking during a sustained fixation task (30-60 s). Micro-saccade rate refers to the number of micro-saccade events per second during sustained fixation, reflecting fixation stability and cortical arousal. It is measured as events per second (events/s).

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  15. Fixation Dispersion

    Fixation dispersion will be assessed using eye tracking during a sustained fixation task (30-60 s). Fixation dispersion refers to the angular spread of gaze position around the fixation target during sustained fixation, quantifying the spatial extent of fixation instability. It is measured in degrees (°).

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  16. Fixation Duration During Free Viewing

    Fixation duration during free viewing will be assessed using eye tracking. Fixation duration refers to the mean duration of individual fixations during free viewing of a standardised stimulus, reflecting attentional dwell time. It is measured in milliseconds (ms).

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  17. Scanpath Variability During Free Viewing

    Scanpath variability during free viewing will be assessed using eye tracking. Scanpath variability refers to the angular variability of the gaze trajectory during free viewing, characterising the spread and consistency of spontaneous viewing patterns. It is measured in degrees (°).

    Time frame: Baseline (pre-intervention), 60 and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

Other outcomes

  1. Breath Alcohol Concentration

    Breath alcohol concentration (BrAC) will be measured using a handheld breathalyzer. BrAC refers to the ethanol concentration in exhaled breath, converted to estimated blood alcohol concentration (BAC) using a standard 1:2100 partition ratio. A target BAC of 0.04-0.06% corresponds to an approximate BrAC of 0.04-0.06 mg/210L. It is measured in mg/210L.

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  2. Peripheral Oxygen Saturation (SpO₂)

    Peripheral oxygen saturation (SpO₂) will be measured using a pulse oximeter. SpO₂ refers to the estimated percentage of oxyhaemoglobin relative to total haemoglobin in peripheral blood, providing a non-invasive measure of systemic oxygenation. It is measured as a percentage (%).

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  3. Pulse Rate

    Pulse rate will be measured using automated sphygmomanometry. Pulse rate refers to the number of arterial pulsations per minute, reflecting heart rate and cardiovascular autonomic response to intervention. It is measured in beats per minute (bpm).

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  4. Systolic Blood Pressure

    Systolic blood pressure will be measured using automated sphygmomanometry. Systolic blood pressure refers to the peak arterial pressure during cardiac contraction, reflecting cardiovascular autonomic response to intervention. It is measured in millimetres of mercury (mmHg).

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  5. Diastolic Blood Pressure

    Diastolic blood pressure will be measured using automated sphygmomanometry. Diastolic blood pressure refers to the minimum arterial pressure during cardiac relaxation, reflecting cardiovascular autonomic response to intervention. It is measured in millimetres of mercury (mmHg).

    Time frame: Baseline (pre-intervention), 30, 60, 90, and 120 minutes post-intervention - during each of the 3 study visits (up to 3 study days total)

  6. Weight

    Weight of participant in kilograms

    Time frame: Baseline (pre-intervention) during each of the 3 study visits (up to 3 study days total)

  7. Height

    Height of the participant in meters

    Time frame: Baseline (pre-intervention) during each of the 3 study visits (up to 3 study days total)

  8. Body Mass Index (BMI)

    Calculated as participant's weight in kilograms divided by the square of participant's height in meters (kg/m\^2).

    Time frame: Calculated at baseline (pre-intervention) during each of the 3 study visits (up to 3 study days total)

07

Study locations

1 of 1 sites recruiting
  • National University of Singapore, E7 Building, Level 7, 15 Kent Ridge Cres
    Singapore, 119276, Singapore
    Recruiting
    • Vicknaswari T, BSc · Contacttv96@nus.edu.sg · +6565165459
    • Najiya S.K. Meethal, PhD · Contactnajiyaskmeethal@nus.edu.sg · +6591183642
    • Raymond P. Najjar, PhD · Principal investigator
    • Najiya S.K. Meethal, PhD · Sub investigator
    • Catherina Josephine Goenadi, MD · Sub investigator
08

References and documents

Publications

  • Silva JBS, Cristino ED, Almeida NL, Medeiros PCB, Santos NAD. Effects of acute alcohol ingestion on eye movements and cognition: A double-blind, placebo-controlled study. PLoS One. 2017 Oct 12;12(10):e0186061. doi: 10.1371/journal.pone.0186061. eCollection 2017. PubMed 29023550 ↗
  • Bardak H, Gunay M, Mumcu U, Bardak Y. Effect of Single Administration of Coffee on Pupil Size and Ocular Wavefront Aberration Measurements in Healthy Subjects. Biomed Res Int. 2016;2016:9578308. doi: 10.1155/2016/9578308. Epub 2016 Jun 29. PubMed 27437402 ↗
  • Wilhelm B, Stuiber G, Ludtke H, Wilhelm H. The effect of caffeine on spontaneous pupillary oscillations. Ophthalmic Physiol Opt. 2014 Jan;34(1):73-81. doi: 10.1111/opo.12094. PubMed 24325436 ↗
  • Redondo B, Vera J, Carreno-Rodriguez C, Molina-Romero R, Jimenez R. Acute Effects of Caffeine on Dynamic Accommodative Response and Pupil Size: A Placebo-controlled, Double-blind, Balanced Crossover Study. Curr Eye Res. 2020 Sep;45(9):1074-1081. doi: 10.1080/02713683.2020.1725060. Epub 2020 Feb 11. PubMed 32011181 ↗
  • Abokyi S, Owusu-Mensah J, Osei KA. Caffeine intake is associated with pupil dilation and enhanced accommodation. Eye (Lond). 2017 Apr;31(4):615-619. doi: 10.1038/eye.2016.288. Epub 2016 Dec 16. PubMed 27983733 ↗
  • Rukmini AV, Milea D, Gooley JJ. Chromatic Pupillometry Methods for Assessing Photoreceptor Health in Retinal and Optic Nerve Diseases. Front Neurol. 2019 Feb 12;10:76. doi: 10.3389/fneur.2019.00076. eCollection 2019. PubMed 30809186 ↗

Individual participant data

Plan to share: Undecided — Individual participant data (IPD) may not be shared due to participant confidentiality, privacy protection, and compliance with institutional or sponsor and regulatory data governance policies.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for May 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
Jun 4, 2026
StartActual
Jun 15, 2026
Primary completionEst.
May 5, 2027
CompletionEst.
Nov 5, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 1, 2026→Jun 15, 2026 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Jun 1, 2026→Jun 15, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07625358
Collaborators
Home Team Science & Technology Agency (HTX)
Responsible party
Raymond P. Najjar, PhD (Assistant Professor, National University of Singapore) — Principal investigator
First posted
Jun 4, 2026
Start date
Jun 15, 2026
Primary completion
May 5, 2027 (estimated)
Completion
Nov 5, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Vicknaswari T, Bsc Optometry
Contact
tv96@nus.edu.sg
+6565165459
Najiya S.K Meethal, PhD
Contact
najiyaskmeethal@nus.edu.sg
+6591183642
Raymond P. Najjar, PhD
principal investigator · Department of Ophthalmology, National University of Singapore (NUS)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion